Time				Day 1 (01.4.2021)	(02.04.2021) Holiday	Day 2 (3.4.2021)
Week 1	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM				Clinics Lecture- MEDICINE IM5.1 Describe and discuss the physiologic and biochemical basis of hyperbilirubinemia		MI 1.1: Overview of bacterial infections and Bacterial Taxonomy
9 AM- 12 PM				Clinical Posting- SCHEDULE MADE (separate roster attached)		AETCOM (9am – 11am) Module 2.1: The foundations of communication – 2 Focused small group session PH 1.1 - (11pm -12pm) Principles of pharmacology and Pharmacotherapeutics
12 PM- 1 PM				MI 1.1: Introduction, History of Microbiology		SDL Pharma 1 Orphan drug, P drug, Essential drugs
2PM – 4PM				PA 13.1 Describe hematopoiesis and extramedullary hematopoiesis PA13.2Describe the role of anticoagulants in hematology		
Time	Day 3 (05.4.2021)	Day 4 (06.4.2021)	Day 5 (07.4.2021)	Day 6 (8.4.2021)	Day 7 (9.4.2021)	Day 8 (10.4.2021)
Week 2	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday

8 AM-9 AM	FM 1.1 Basic Aspects of Forensic Medicine, State Medicine, Legal Medicine and Medical Jurisprudence FM 1.2 History of Forensic Medicine	Patho PA1.1 role of a pathologist in diagnosis & management of disease; lecture	PH 1.4- Describe and evaluate Pharmacokinetics - I	Clinics Lecture- MEDICINE IM5.2 Describe and discuss the aetiology and pathophysiology of liver injury IM5.3 Describe and discuss the pathologic changes in various forms of liver disease	Clinics Lecture SURGERY SU 2.1 Describe pathophysiology of shock & principles of resuscitation including fluid replacement and monitoring SU 2.2 Describe the clinical features of shock and its appropriate treatment	MI 1.1: Identification of Bacteria (Conventional & automated, Molecular)
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9am – 11am) Module 2.1: The foundations of communication – 2 Focused small group session - 2 hours (11pm -12pm) PH 1.4- Describe and evaluate Pharmacokinetics - II
12 PM- 1 PM	PH 1.11- Routes of drug administration	MI 1.1: Morphology of Bacteria	Patho - PA1.2 Enumerate common definitions and terms used in Pathology	MI 1.4: Sterilization and Disinfection	Patho PA1.3 Describe the history and evolution of Pathology	SDL Pathology PA2.2 Cell injury.

DEAN

2PM - 4PM	FMT PRACTICAL BATCH 1 INTRODUCTION TO PRACTICAL ASPECTS	MI 1.2: Different types of Microscope and Microscopy	Batch -1 (Pharma) PH 2.1- Various dosage forms (oral/local/ parenteral;solid/liquid)	PA13.3 Define and classify anemia IM9.1,9.2,9.6 PE 29.1,BI6.11, BI6.12 MI 2.4 Infections causing anemia	Batch -1 (Patho) Departmental orientation	
	CM Practical batch 2: Introduction of practical aspects CM 7.4 practical batch 2 Define, calculate and interpret morbidity and mortality indicators based on given set of data	Departmental orientation	Batch 2 – (Micro) MI 1.2: Different types of Microscope & Microscopy		Batch 2 – (Pharma) PH 2.1- Various dosage forms (oral/local/parenteral; solid/liquid)	
Time	Day 9 (12.4.2021)	Day 10 (13.4.2021)	Day 11 (14.4.2021)	Day 12 (15.4.2021)	Day 13 (16.4.2021)	Day 14 (17.4.2021)
Week 3	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM 7.1 : Define Epidemiology and describe and enumerate the principles, concepts and uses CM 7.3: Enumerate, describe and discuss the sources of epidemiological data	Patho PA2.1 Causes, mechanisms, types and effects of cell injury and their clinical significance	PH 1.5 - Describe and evaluate Pharmacodynamics - I	Clinics Lecture MEDICINE IM5.4 Describe and discuss the epidemiology, microbiology, immunology and clinical evolution of infective (viral) hepatitis	Clinics Lecture SURGERY SU 1.1 Describe the Basic concepts of homeostasis, enumerate the metabolic changes in injury and their mediators SU 1.2 Describe the factors that affect the metabolic response to injury SU 1.3 Describe the basic concepts of perioperative care	MI 1.1: Overview of Viral infections and General Virology
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM Module 2.1: The foundations of communication – 2, Skills lab session – 1 Hr Pandemic 2.1Infection Control: Part II Air borne

						precautions Contact Precautions Infection Control Committee (10-11 am) (11pm -12pm) PH 1.59 - Essential medicines, FDC, OTC drugs, herbal medicines
12 PM- 1 PM	PH 1.4 - Describe and evaluate Pharmacokinetics - III	MI 1.1: Bacterial Genetics	Patho PA2.2 Cell injury etilology and morphology of cell injury	MI 1.6: Antimicrobials, AMR, AST, Monitoring of AMT, Antimicrobial stewardship	Patho PA2.4 Cell death- types, mechanisms, necrosis, apoptosis, autolysis, PA 2.7 Cellular aging and apoptosis	MI 1.1: Physiology of Bacteria SDL
2PM – 4PM	FMT PRACTICAL BATCH 2 INTRODUCTION TO PRACTICAL ASPECTS	Batch -1 (Micro) MI 1.5: Sterilization and Disinfection (including CSSSD visit)	Batch -1 (Pharma) Prescription writing, DOAP	PA13.4 Enumerate and describe the investigation of anemia IM9.7,9.8,9.9.,9.8,9 .10, IM 9.13	Batch -1 (Patho) PA13.5 Perform, Identify and describe the peripheral blood picture in anemia DOAP session	
	CM 7.4 practical batch 1 Itroductio to practical aspects Define, calculate and interpret morbidity and mortality indicators based on given set of data	Batch 2 Path PA13.5 Peripheral blood picture in anemia DOAP session	Batch 2 – (Micro) MI 1.5: Sterilization and Disinfection (including CSSSD	PH 1.55 Colony stimulating factors and plasma expanders	Batch 2 – (Pharma) Prescription writing, DOAP	
Time	Day 15 (19.4.21)	Day 16 (20.4.21)	Day 17 (21.4.21)	Day 18 (22.4.21)	Day 19 (23.4.21)	Day 20 (24.4.21)
Week 4 8 AM-9 AM	Monday FM 3.1 IDENTIFICATION - I	Tuesday Patho PA 2.5; Describe and discuss pathologic calcifications, gangrene	Wednesday Pharma – PH 5.1 Communicate with the patient with empathy and ethics on all aspects of drug use	Thursday Clinics Lecture MEDICINE IM5.5 Describe and discuss the pathophysiology and clinical	Friday Clinics Lecture SURGERY SU 3.1 Describe the indications and appropriate use of blood and blood products and complications of blood transfusion	Saturday AETCOM Module 2.1: The foundations of communication – 2, Skills lab session – 1 Hr Reflections

				evolution of alcoholic liver disease		Pandemic 2.11nfection
						Control: Part II Air born precautions Contact Precautions Infection Control Committee (10- am)
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Pharma 11-12pm PH 1.64 - Overview of drug development, clinic trial and good clinical practice
12 PM- 1 PM	PH 1.5 - Describe and evaluate Pharmacodynamics - II	MI: 1.1: Overview of parasitic infections and General Parasitology	Patho PA2.6; Describe and discuss cellular adaptations: atrophy, hypertrophy, hypertrophy, hyperplasia, metaplasia, dysplasia	MI 1.1: Overview of fungal infections and General Mycology	Patho PA3.1; Describe the pathogenesis and pathology of amyloidosis	Sports
2PM - 4PM	FMT PRACTICAL - BATCH 1 DETERMINATION OF RACE	Batch -1 (Micro) MI 1.1:Culture Media and Culture Methods	Batch -1 (Pharma) PH 3.1 Prescription writing DOAP	PA14.1 Describe iron metabolism PE 13.1 PH 1.35	Batch -1 (Patho) PA2.8; Identify and describe cell injury features in gross and microscopic specimens DOAP session	
	CM Practical Batch 2: CM7.6 Enumerate and evaluate the need of screening tests	Batch 2 – (Patho) PA2.8; Cell injury features in gross and microscopic specimens DOAP session	Batch 2 – (Micro) MI 1.1:Culture Media and Culture Methods	Drugs used in anemia	Batch 2 – (Pharma) PH 3.1 Prescription writing DOAP	

5	Time	Day 1/Monday	Day 2 /Tuesday	Day 3 /Wednesday	Day 4 / Thursday	Day 5 / Friday	Day 6 /Saturday	

Week 5	26.4.21	27.4.21	28.4.21	29.4.21	30.4.21	1.5.21
8 AM-9 AM	CM 7.5: Enumerate, define, describe and discuss epidemiological study designs	Patho PA4.1 General features of acute and chronic inflammation	Pharma – PH 1.2 Evidence based medicine (SGD 1)	Clinics Lecture MEDICINE IM8.1 Describe and discuss the epidemiology, aetiology and the prevalence of primary and secondary hypertension IM8.5 Describe and discuss the differences between primary and secondary hypertension IM8.7 Describe and discuss the clinical manifestations of the various aetiologies of secondary causes of hypertension	Clinics Lecture SURGERY SU 5.1 Describe normal wound healing and factors affecting healing	MI 1.8: Components of Immune System-Organs, cells and products
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM Module 2.1: The foundations of communication – 2 Discussion and closure – 1 hour Pandemic 2.1Infection Control: Part II Air borne precautions Contact Precautions Infection Control Committee (10-11 am) (11pm -12pm) Pharma – PH 1.6 & 1.7 ADR and Pharmacovigilance (SGD 2)

12 PM- 1 PM	Pharma – PH 1.9 Nomenclature of drugs – branded/generic (SGD 3)	MI 1.3: Epidemiology of infectious diseases	Patho PA4.2 Mediators of acute inflammation	MI 1.7: Immunity (Innate and Acquired)- Immunological mechanisms in health	Patho PA4.2 Mediators of acute inflammation Contd.	SDL Pharma 2 Pharmacogenetics and pharmacogenomics
2PM – 4PM	FMT PRACTICAL - BATCH - 2 DETERMINATION OF RACE	Batch -1 (Micro) MI 1.2: Gram staining -1 MI 1.1: Morphology of bacteria, growth curve	Batch -1 (Pharma) PH 2.3 Setting up of an intravenous drip (DOAP)	PA14.2 Describe the etiology, investigations and differential diagnosis of microcytic hypochromic anemia PE 29.2 PE 13.2 PE 13.3 PE 13.4 PE 13.5 IM 9.9 PH 1.35 Pharmacotherapy of anemia	Batch -1 (Patho)PA4.4; Acute inflammation in specimens DOAP session	
	CM batch 1: CM7.6 Enumerate and evaluate the need of screening tests	Batch 2 – (Patho) PA4.4; Acute inflammation gross and microscopic specimens DOAP session	Batch 2 – (Micro) MI 1.2: Gram staining -1 MI 1.1: Morphology of bacteria, growth curve	Pandemic 2.1Infection Control: Part II Air borne precautions Contact Precautions Infection Control Committee (3-4 pm)	Batch -2 (Pharma) PH 2.3 Setting up of an intravenous drip (DOAP)	

Time	3.5.2021	4.5.2021	5.5.2021	6.5.2021	7.5.2021	8.5.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.1 IDENTIFICATION - I (CONT)	Patho PA4.2 Mediators of acute inflammation SGD	Pharma PH 1.13 Describe the MOA,types, dosage,S/E of drugs of Adrenergic System - I	Clinics Lecture OBGY OG2.1 Describe and discuss the development and anatomy of the female reproductive tract, relationship to	Clinics Lecture SURGERY SU 5.2 Elicit, document and present a history in a patient with wounds SU 5.3 Differentiate the various types of wound, plan and	MI 1.8: Antigen-Antibody Reaction 1

				other pelvic organs, applied anatomy as related to Obstetrics and Gynaecology. (part 1)	observe management of wounds SU 5.4 Discuss the medicolegal aspects of wound	
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.2 The foundations of bioethics large group session - 2 hours Pharma (11pm -12pm) PH 1.13 Describe the MOA,types, dosage,S/E of drugs of Adrenergic System - II
12 PM- 1 PM	Pharma PH 1.8 -Drug Interactions (SGD 4)	MI 1.8: Antigen	Patho PA4.3 Chronic inflammation	MI 1.8: Antibody	Patho PA5.1 Repair and regeneration ,wound healing and its types SU 5.1	SDL Pathology PA 6.4 Normal haemostasis etiopathogenesis and consequences of thrombosis SDL
2PM - 4PM	FMT PRACTICAL - BATCH 1 FM 14.9 EXAMINATION OF SKULL & MANDIBLE	Batch -1 (Micro) MI 8.9 & MI 8.10: Specimen collection and transport	Batch -1 (Pharma) PH 2.2 - ORS preparation	PA14.3 Identify and describe the peripheral smear in microcytic anemia DOAP session IM9.11, MI 2.6, MI 2.5	Batch -1 (Patho)PA4.4; Acute inflammation in specimens DOAP session	
	Batch 2: CM 7.7 Describe and demonstrate the steps in the Investigation of an epidemic of communicable disease and describe the principles of control measures	Batch 2 – (Patho)PA4.4; Acute inflammation in specimens DOAP session Contd.	Batch 2 – (Micro) MI 8.9 & MI 8.10: Specimen collection and transport	Identify the causative agents of Malaria and Leishmaniasis from smear	Batch 2 – (Pharma) PH 2.2 - ORS preparation	
Time	10.5.2021	11.5.2021	12.5.2021	13.5.2021	14.5.2019 Friday	15.5.2021 Saturday

					Holiday	
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM 7.8: Describe the principles of association, causation and biases in epidemiological studies	Patho PA 6.1 Edema, types, pathogenesis and clinical correlations SGD	Pharma PH 1.13 Drugs used in glaucoma Adrenergic System - IV	Clinics Lecture OBGY OG2.1 Describe and discuss the development and anatomy of the female reproductive tract, relationship to other pelvic organs, applied anatomy as related to Obstetrics and Gynaecology. (part 2)		MI 1.8: Immune Responses: Cell-mediated and Antibody- mediated
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting		AETCOM (9-11) Module 2.3: Health care as a right Participatory student seminar - 2 hrs Pharma (11pm -12pm) PH 1.14 Describe the MOA,types, dosage,S/E of drugs of Cholinergic System - I
12 PM- 1 PM	Pharma PH 1.13 Describe the MOA,types, dosage,S/E of drugs of Adrenergic System - III	MI 1.8: Antigen- Antibody Reaction 2	Patho PA 6.3 Shock, its pathogenesis and its stages SGD SU2.1	MI 1.8: Complement		MI 1.1: Plague
2PM – 4PM	FMT PRACTICAL - BATCH 2 FM 14.9 EXAMINATION OF SKULL & MANDIBLE	Batch -1 (Micro) MI 1.1 & MI 1.2: Laboratory diagnosis of viral & parasitic infections. Stool microscopy-1, PBS	Batch -1 (Pharma) PH 2.4 Dosage Calculation	PA16.1 Define and classify hemolytic anemia PA 10.1 Pathogenesis and pathology of		

Batch 1: CM 7.7 Describe and demonstrate the steps in the Investigation of an epidemic of communicable disease and describe the principles of control measures	Batch 2 – (Patho)PA 6.2Hyperemia, congestion, hemorrhage SGD	Batch 2 – (Micro) MI 1.1 & MI 1.2: Laboratory diagnosis of viral & parasitic infections. Stool microscopy-1, PBS	malaria SGD MI 2.5: Malaria 1		
--	---	--	----------------------------------	--	--

Time	17.5.2021	18.5.2021	19.5.2021	20.5.2021	21.5.2021	22.5.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.2 IDENTIFICATION - II	Patho PA6.5 Embolism ,causes and common types SGD	Pharma PH 1.1 Describe the MOA,types, dosage,S/E of drugs of Cholinergic System - III	Clinics Lecture OBGY OG3.1 Describe the physiology of ovulation, menstruation, fertilization, implantation and gametogenesis.(par t 1)	Clinics Lecture SURGERY SU 4.1 Elicit document and present history in a case of Burns and perform physical examination. Describe Pathophysiology of Burns.	MI 1.1: Blood stream infections, sepsis, septic shock, CRBSI
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.4: Working in a health care team "Tag along" session in hospital- 2 hours Pharma (11pm -12pm) PH 1.31 Drugs for dyslipidemia
12 PM- 1 PM	Pharma PH 1.1 Describe the MOA,types, dosage,S/E of drugs of Cholinergic System - II	MI 1.8: Immune Responses: Cell- mediated and Antibody-mediated 2	Patho PA6.6 Ischaemia/infarction its types, etiology, morphologic changes SGD	MI 1.9: Immunoprophylaxi s & Immunohematolog	Patho PA7.1 Neoplasia. Definition,characteristi cs Difference benign & maignant neoplams IM 13.3, 13.4	Pandemic 2.2 Emerging and Re-emerging infections, early identification and control of new infections

2PM – FMT PRACTICAL - 4PM BATCH 1 FM 14.9 EXAMINATION OF UPPER LIMB BONES	MI 1.1, 1.2: Laboratory diagnosis of fungal infections Normal Microbial Flora	Batch -1 (Pharma) PH4.2 Computer Assisted Learning (CAL)	PA16.2 Describe the pathogenesis and clinical features and hematologic indices of	Batch -1 (Patho)PA 6.2Hyperemia, congestion, hemorrhage SGD	Sports
Batch 2: CM 3.8: Describe the mode of action, application cycle of commonly used insecticides and rodenticides (integration with pharma)	Batch 2 – (Patho)PA 6.7Infarction in specimen DOAP session	MI 1.1, 1.2: Laboratory diagnosis of fungal infections Normal Microbial Flora	hemolytic anemia MI 2.5& MI 1.1: Malaria 2 & Babesiosis	Batch 2 – (Pharma) PH4.2 Computer Assisted Learning (CAL)	

Time	24.5.2021	25.5.2021	26.5.2021 HOLIDAY	27.5.2021	28.5.2021	29.5.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM 3.6: Describe the role of vectors in the causation of diseases. Also discuss National Vector Borne disease Control Program (integration micro) CM 3.7: Identify and describe the identifying features and life cycles of vectors of Public Health importance and their control measures (integration micro)	PathoPA 7.2 Molecular basis of cancer IM 13.2		Clinics Lecture OBGY OG3.1 Describe the physiology of ovulation, menstruation, fertilization, implantation and gametogenesis. (part 2)	Clinics Lecture SURGERY SU 4.2 Describe Clinical features. Diagnose type and extent of burns and plan appropriate treatment. SU 4.3 Discuss the medicolegal aspects in burn injuries	MI 1.1: Rickettsial infections
9 AM- 12 PM	Clinical Posting	Clinical Posting		Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.4: Working in a health care team

					"Tag along" session in hospital- 2 hours Pharma (11pm -12pm) PH 1.16 Describe the MOA,types, dosage,S/E of Autacoids
12 PM- 1 PM	Pharma PH 1.16 Describe the MOA,types, dosage,S/E of Autacoids	MI 2.1, 2.2: Infections of CVS	MI 3.3: Enteric (typhoid) fever	Patho PA 7.4 effects of tumor on the host, paraneoplastic syndrome PA 7.5 Describe immunology and the immune response to cancer,BI10.2	SDL Pharmacology 3 Anti-diuretics
2PM – 4PM	FMT PRACTICAL - BATCH 2 FM 14.9 EXAMINATION OF UPPER LIMB BONES	MI 1.8, 8.15: Antigen-Antibody Reaction	PA 16.3 Pathogenesis, features, hematologic indices and peripheral blood	Batch -1 (Patho)PA 6.7 Infarction in specimen DOAP session	Pandemic 2.2 Emerging and Re-emerging infections, early identification and control of new infections
	Batch 1 CM 3.8: Describe the mode of action, application cycle of commonly used insecticides and rodenticides (integration with pharma)	Batch 2 – (Patho)PA 7.3 carcinogens, process of carcinogenesis SGD IM 13.1,,IM 13.15, MI8.3,BI10.1, BI7.7	picture of sickle cell anemia and thalassemia PE 29.4, BI5.2 PH 1.47 Anti Malarial drugs	Batch 2 – (Pharma) PH 2.4 - Dosage Calculation	

Time	31.5.2021	1.6.2021	2.6.2021	3.6.2021	4.6.2021	5.6.2021

		Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.2 IDENTIFICATION - II (CONT)	Patho PA 8.1 Cytology PA 8.2 Exfoliative cytology SGD	Pharma PH 1.24 -Evaluate the indications, C/I, S/E of diuretics Renal	Clinics Lecture MEDICINE IM8.2 Describe and discuss the pathophysiology of hypertension IM8.3 Describe and discuss the genetic basis of hypertension IM8.4 Define and classify hypertension	Clinics Lecture OBGY OG4.1 Describe and discuss the basic embryology of fetus, factors influencing fetal growth and development , anatomy and physiology of placenta, and teratogenesis (part1)	MI 1.1: Dengue, chikungunya,and Zikavirus
9 AM- 12 PM		Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.4: Working in a health care team- SGD - 2 hrs Pharma (11pm -12pm) PH 1.26 Describe the MOA,types, dosage,S/E of RAAS
12 PM- 1 PM	Pharma PH 1.24 Renal - describe the mech of diuretics	MI 2.7: HIV	PathoPA 9.1 Principles and mechanisms involved in immunity SGD BI10.3	MI 2.7: HIV 2	Patho PA 9.2 Describe the mechanism of hypersensitivity reactions SGD	SDL Pathology Patho PA 9.5 Autoimmune disorders-SLE DR 16.1 bedside discussion
2PM – 4PM	FMT PRACTICAL - BATCH 1 FM 14.9 EXAMINATION OF PELVIC BONE & SACRUM Batch 2: CM 5.6 Enumerate and discuss the National Nutrition Policy, important national nutritional Programs including	MI 3.4, 8.15: Enteric (typhoid) fever,Brucellosis,Leptos pirosis MI 1.2: Gram staining - 2 Batch 2 – (Patho)PA 8.3diagnostic cytology, staining ,interpretation DOAP	Batch -1 (Pharma) PH 4.2 Computer Assisted Learning (CAL) MI 3.4, 8.15: Enteric (typhoid) fever,Brucellosis,Leptospirosi s MI 1.2: Gram staining -2	PA16.4 Pathogenesis, hematologic indices and peripheral blood picture of Acquired hemolytic anemia PH 1.47 Anti Malarial drugs	Batch -1 (Patho)PA 7.3 carcinogens,process of carcinogenesis SG D ,IM 13.1,IM 13.15, MI8.2,BI10.1, BI7.7 Batch 2 – (Pharma) PH 4.2 Computer Assisted Learning (CAL)	Pandemic 2.2 Emerging and Re-emerging infections, early identification and control of new infections

the Integrated Child			
Development			
Services Scheme			
(ICDS) etc			

Time	7.6.2021	8.6.2021	9.6.2021	10.6.2021	11.6.2021	12.6.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM 5.1 Describe the common sources of various nutrients and special nutritional requirements according to age, sex, activity, physiological conditions (integration with general medicine/paed)	PathoPA 9.3 HLA system , immune principles in transplant,transplant rejection SGD	Pharma PH 1.27 - Describe the MOA,types, dosage,S/E of drugs for Hypertension - II	Clinics Lecture MEDICINE IM8.8 Describe, discuss and identify target organ damage due to hypertension	Clinics Lecture OBGY OG4.1 Describe and discuss the basic embryology of fetus, factors influencing fetal growth and development, anatomy and physiology of placenta , and teratogenesis(part2)	MI 2.5: Lymphatic filariasis
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.5: Bioethics continued – patient autonomy and decision makingIntroduction and group formation - 1 hour Case introduction - 1 hour Pharma (11pm -12pm) PH 1.55 Describe the MOA,types, dosage,S/E of Immunomodulators
12 PM- 1 PM	Pharma PH 1.27 - Describe the MOA,types, dosage,S/E of drugs for Hypertension	MI 1.1: Other viral hemorrhagic fever- Kyasanuar forest disease, Ebola and Marburg virus, Hantaviruses	Patho PA 9.4 Define autoimmunity. Enumerate autoimmune disorders IM 7.1, IM 7.2, IM 7.16	MI 2.5: Leishmaniasis	PathoPA 9.6 Define and describe the pathogenesis and pathology of HIV and AIDS IM 6.5, IM 6.6, IM 6.10, IM 6.19, MI8.2,MI 2.7	SDL Microbiology MI 1.1: Trypanosomiasis and Schistosomiasis

2PM - 4PM	FMT PRACTICAL - BATCH 2 FM 14.9 EXAMINATION OF PELVIC BONE & SACRUM Batch 1:	MI 1.2: Acid fast staining 1	Batch -1 (Pharma) PH 4.1 Drug administration in Mannequin	PA16.5 Describe the peripheral blood picture in different hemolytic anaemias	Batch -1 (Patho)PA 8.3Obderve diagnostic cytology and its staining DOAP session	Pandemic 2.2 Emerging and Re-emerging infections, early identification and control of new infections
	CM 5.6 Enumerate and discuss the National Nutrition Policy, important national nutritional Programs including the Integrated Child Development Services Scheme (ICDS) etc	Batch 2 – (Patho) PA 10.2pathogenesis and pathology of Cysticercosis SGD	MI 3.4, 8.15: Enteric fever,Brucellosis,Leptospir osis MI 1.2: Gram staining -2		Batch 2 – (Pharma) PH 4.1 Drug administration in Mannequin	

Time	14.6.2021	15.6.2021	16.6.2021	17.6.2021	18.6.2021	19.6.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.3 MECHANICAL INJURIES & WOUNDS - I	PathoPA 9.7 Pathogenesis of other common autoimmune diseases	Pharma PH 1.16 Describe MOA,types,dosage,S/E of drugs for Rheumatoid Arthritis	Clinics Lecture MEDICINE IM9.1 Define, describe and classify anemia based on red blood cell size and reticulocyte count	Clinics Lecture OBGY OG5.1 Describe, discuss and identify pre-existing medical disorders and discuss their management; discuss evidence-based intrapartum care	MI 8.5,8.6: Needle stick injury
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making, SDL- 2 hrs Pharma (11pm -12pm) PH 1.16 - Describe MOA,types,dosage, S/E of drugs for gout

12 PM- 1 PM	Pharma PH 1.55 Describe MOA,types,dosage, S/E of Immunomodulators	MI 1.1: Systemic mycosis and Candidiasis	Patho PA 10.4 pathogenesis and pathology of common bacterial, viral, protozoal, helminthic diseases SGD	MI 8.5,8.6, 8.7: Hospital acquired infection	PA 10.4 pathogenesis and pathology of common bacterial, viral, protozoal, helminthic diseases SGD	Sports
2PM – 4PM	FMT PRACTICAL - BATCH 1 & 2 REVISION CLASS	MI 1.2: Acid fast staining 2	Batch -1 (Pharma) PH 4.1 Drug administration in Mannequin	PE24.1, 24.2 & 25.1 diarrheal dehydration,Malabs orption	Batch -1 PA 10.2pathogenesis and pathology of Cysticercosis SGD	
	CM Batch 1 & 2 CM5.7 Describe food hygiene CM 5.8 Describe and discuss the importance and methods of food fortification and effects of additives and adulteration	Batch 2 – (Patho) PA10.3pathogenesis and pathology of leprosySGD	MI 1.2: Acid fast staining 1	MI 3.1: infective agents causing Diarrheal diseases	Batch 2 – (Pharma) PH 4.1 Drug administration in Mannequin	

Time	21.6.2021	22.6.2021	23.6.2021	24.6.2021	25.6.2021	26.6.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM						
9 AM- 12 PM						

	Internal Assessment	Internal Assessment
12 PM- 1 PM		
2PM - 4PM		

Time	28.6.2021	29.6.2021	30.6.2021	1.7.2021	2.7.2021	3.7.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM						
9 AM- 12 PM		Internal Assessment				

DEAN

12 PM- 1 PM	
2PM – 4PM	

Time	5.7.2021	6.7.2021	7.7.2021	8.7.2021	9.7.2021	10.7.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM CM8.1 Describe and discuss the epidemiological and control measures including the use of essential laboratory tests at the primary care level for communicable diseases (Infectious disease	PA 11.1 pathogenesis of common cytogenetic abnormalities and mutations in childhood SGD	Pharma PH 1.31 Drugs used in AMI and fibrinolytics	Clinics Lecture MEDICINE IM9.2 Describe and discuss the morphological characteristics, aetiology and prevalence of each of the causes of anemia IM9.7 Describe and discuss the	Clinics Lecture SURGERY SU 6.1 Define and describe the aetiology and pathogenesis of surgical infections SU 6.2 Enumerate Prophylactic and therapeutic antibiotics. Plan appropriate management	CM 8.5 Describe and discuss the principles of planning,implementing and evaluating control measures for disease at community level bearing mind public health importance the disease

	epidemiology)			meaning and utility of various components of the hemogram			
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making, ANCHORING LECTURE AND CASE RESOLUTION- 1+1 hrs Pharma (11pm -12pm) PH 1.25,1.31 Antiplatelet drugs	
12 PM- 1 PM	Pharma PH 1.28 Drugs used in Angina	MI 3.1: Normal commensals Gastrointestinal infective syndromes	PA 11.3 pathogenesis of common storage disorders in infancy and childhood SGD	MI 3.1: Cholera and halophilic Vibrio infections	PA 11.2 pathology of tumor and tumour like conditions in infancy and childhood SGD	SDL Pharma 4 PH 1.27 Management of hypertension in pregnancy	
2PM – 4PM	FMT PRACTICAL - BATCH 1 FM 14.9 EXAMINATION OF LOWER LIMB BONES	Batch -1 (Micro) MI 3.1: Giardiasis Intestinal coccidian parasites and microsporidia infections MI 1.2: Stool microscopy-2	Batch -1 (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case I (DOAP)	PA25.1Describe bilirubin metabolism, enumerate the etiology and pathogenesis of jaundice, distinguish between	Batch -1 (Patho) PA10.3pathogenesis and pathology of leprosy SGD	Pandemic 2.3 Sample Collection, Microbial diagnosis, Serologic tests and their performance parameters	(
	Batch 2: Medical entomology CM 3.7:Identify and describe the identifying features and life cycles of vectors of Public Health importance and their control measures	Batch 2 – (Patho) PA 15.1 metabolism of Vitamin B12, etiology and pathogenesis of B12 deficiency SGD	Batch 2 – (Micro) MI 3.1: Giardiasis Intestinal coccidian parasites and microsporidia infections MI 1.2: Stool microscopy- 2	direct and indirect hyperbilirubinemia IM 5.1, IM 5.2,IM 5.3	Batch 2 – (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case I (DOAP)		

Formatted: Highlight

DEAN

Time	12.7.2021	13.7.2021	14.7.2021	15.7.2021	16.7.2021	17.7.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.3 MECHANICAL INJURIES & WOUNDS - II	Patho PA 12.1 pathogenesis of disorders caused by air pollution, tobacco and alcohol SDL	Pharma PH 1.31 Drugs used in AMI	Clinics Lecture MEDICINE IM9.8 Describe and discuss the various tests for iron deficiency IM9.14 Describe the national programs for anemia prevention	Clinics Lecture SURGERY SU 7.1 Describe the Planning and conduct of Surgical audit SU 7.2 Describe the principles and steps of clinical research in General Surgery	CM 8.6 Educate and train health workers in disease surveillance, control & treatment and health education
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.6: Bioethics continued: Case studies on autonomy and decision making Introduction of case-1hr SDL-1Hr Pharma (11pm -12pm) PH 1.29 Describe the MOA, types and doses of drugs in CHF

12 PM- 1 PM	Pharma PH 1.31 Anti coagulants	MI 3.1: Intestinal amoebiasis Balantidiasis	Patho PA 12.3 pathogenesis of obesity and its consequences SGD IM14.2,,14.3,14.4,14.5 PE11.1, PE 11.2, BI8.1, BI8.4	MI 3.5: Food poisoning- Bacillus cereus, Clostridium botulinum, mycotoxins Antibiotic associated diarrhea	PA 12.2 pathogenesis of protein calorie malnutrition and starvation SGD BI8.2	SDLPathology PA25.2 Describe the pathophysiology and pathologic changes seen in hepatic failure and their clincial manifestations, complications and consequences
2PM – 4PM	FMT PRACTICAL - BATCH 2 FM 14.9 EXAMINATION OF LOWER LIMB BONES	Batch -1 (Micro) MI 3.1: Shigellosis Nontyphoidal salmonellosis Diarrheogenic E.coli MI 1.2: Gram staining-3	Batch -1 (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case II	PA25.3 Describe the etiology and pathogenesis of viral and toxic hepatitis: distinguish the causes of hepatitis based on the	Batch -1 (Patho) PA 15.1 metabolism of Vitamin B12, etiology and pathogenesis of B12 deficiency PE 29.3SGD	Pandemic 2.3 Sample Collection, Microbial diagnosis, Serologic tests and their performance parameters
	Batch 1 Medical entomology CM 3.7:Identify and describe the identifying features and life cycles of vectors of Public Health importance and their control measures	Batch 2 – (Patho) PA 15.3 peripheral blood picture of macrocytic anemia DOAP	Batch 2 – (Micro) MI 3.1: Shigellosis Nontyphoidal salmonellosis Diarrheogenic E.coli MI 1.2: Gram staining-3	clinical and laboratory features. Describe the pathology, complications and consequences of hepatitis PE 26.1, PE 26.2, PE 26.9, IM 5.4, IM 5.7, MI 3.7, MI 3.8 PH 1.16, 1.44 Drugs causing hepatitis	Batch 2 – (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case II	

Time	19.7.2021	20.7.2021	21.7.2021	22.7.2021	23.7.2021	24.7.2021
			Holiday			
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday

8 AM-9 AM	CM CM8.1 Describe and discuss the epidemiological and control measures including the use of essential laboratory tests at the primary care level for communicable diseases Infectious disease epidemiology (part 2)	PA 15.2Describe lab investigations of macrocytic anemia PA15.4 megaloblastic and non- megaloblastic macrocytic anemia SGD		Clinics Lecture MEDICINE IM9.11 Describe the indications and interpret the results of a bone marrow aspirations and biopsy	Clinics Lecture SURGERY SU 8.1 Describe the principles of Ethics as it pertains to General Surgery SU 8.2 Demonstrate professionalism and empathy to the patient undergoing General Surgery SU 8.3 Discuss medicolegal issues in surgical practice	CM 8.7 Describe the principles of management of information systems
9 AM- 12 PM	Clinical Posting	Clinical Posting	HOLIDAY	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.6: Bioethics continued: Case studies on autonomy and decision making contd. SDL-1Hr Anchoring Lecture-1hr Pharma (11pm -12pm) PH 1.30 Describe the MOA, types,S/E of antiarrhythmic drugs
12 PM- 1 PM	Pharma PH 1.29 S/E indications and C/I of drugs in CHF	MI 3.1: Intestinal nematodes- Ascaris, hookworm, Trichuris, Enterobius and Strongyloides		MI 3.1: Intestinal cestode infections - Diphyllobothrium latum ,Taenia, Hymenolepis Intestinal trematodes infections	PA17.1 pathogenesis and findings in aplastic anemia SGD	SDL Micro MI 3.1: Viral gastroenteritis

2PM – 4PM	FMT PRACTICAL - BATCH 1 FM 14.9 EXAMINATION OF BUNDLE OF BONES	Batch -1 (Micro) MI 3.6 MI 3.1: Helicobacter infection,Campyloba cter, Yersiniosis MI 1.2: Stool microscopy-3	PA25.4 Describe the pathophysiology, pathology and progression of alcoholic liver disease including cirrhosis PE 26.3,	Batch -1 (Patho) PA 15.3 peripheral blood picture of macrocytic anemia DOAP	Pandemic 2.3 Sample Collection, Microbial diagnosis, Serologic tests and their performance parameters
	CM practical batch 2 Medical etomology part 2 CM 3.7:Identify and describe the identifying features and life cycles of vectors of Public Health importance and their control measures	Batch 2 – (Patho) PA 17.2 Enumerate the indications and describe the findings in bone marrow aspiration and biopsy DOAP	IM 5.5 PH 1.21 Describe effects acute and chronic ethanol intake with management	Batch 2 – (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case VII (DOAP)	

Time	26.7.2021	27.7.2021	28.7.2021	29.7.2021	30.7.2021	31.7.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.3 MECHANICAL INJURIES & WOUNDS - III	PA 17.2 Enumerate the indications and describe the findings in bone marrow aspiration and biopsy SGD IM 9.12	Pharma PH 1.32 S/E and Contraindications of drugs of COPD and BA	Clinics Lecture MEDICINE IM9.12 Describe, develop a diagnostic plan to determine the aetiology of anemia IM9.21 Determine the need for specialist consultation	Clinics Lecture SURGERY SU 9.1 Choose appropriate biochemical, microbiological, pathological, imaging investigations and interpret the investigative data in a surgical patient	CM 9.5 Describe the methods of population control
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.6: Bioethics continued: Case studies on autonomy and decision

						making contd. CLOSURE-1Hr Pharma (11pm -12pm) PH 1.17 Describe the MOA types and S/E of Local Anaesthetics
12 PM- 1 PM	Pharma PH 1.32 Drugs used in COPD and Bronchial Asthma	MI 3.7: Agents of Viral Hepatitis 1	Patho PA 18.1 causes of leucocytosis leucopenia lymphocytosis and leukemoid reactions SGD	MI 3.7: Agents of Viral Hepatitis 2	Patho PA 18.1 causes of leucocytosis leucopenia lymphocytosis and leukemoid reactions contd. SGD	Sports
2PM – 4PM	FMT PRACTICAL - BATCH 2 FM 14.9 EXAMINATION OF BUNDLE OF BONES	Batch -1 (Micro) MI 4.3: Leprosy MI 1.2: Gram staining-4	Batch -1 (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case III	PA25.5 Describe the etiology, pathogenesis and complications of portal hypertension PE26.4, IM 5.6	Batch -1 PA 17.2 Enumerate the indications and describe the findings in bone marrow aspiration and biopsy DOAP	
	part 2 CM 3.7:Identify and describe the identifying features and life cycles of vectors of Public Health importance and their control measures	Batch 2 – (Patho) PA 16.6 peripheral blood smear to identify hemolyti anaemia from it DOAP	Batch 2 – (Micro) MI 3.6, MI 3.1: Helicobacter infection,Campylobacter, Yersiniosis MI 1.2: Stool microscopy- 3		Batch 2 – (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case III	

T	ime	2.8.2021	3.8.2021	4.8.2021	5.8.2021	6.8.2021	7.8.2021
		Monday	Tuesday	Wednesday	Thursday	Friday	Saturday

8 AM-9 AM	CM CM8.1 Describe and discuss the epidemiological and control measures including the use of essential laboratory tests at the primary care level for communicable diseases (Malaria)	Patho PA 18.2 pathogenesis classification, features, hematologic features of acute leukemia PE 29.8 SGD	Pharma PH 1.18 doses S/E and C/I of General Anaesthetics	Clinics Lecture OBGY OG5.2 Determine maternal high risk factors and verify immunization status	Clinics Lecture SURGERY SU 9.2 Biological basis of early detection of cancer and multidisciplinary approach in management of cancer	CM 9.6 Describe the National Population Policy
9 AM- 12 PM		Clinical Posting	ical Posting Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.7: Bioethics continued: Case studies on autonomy and decision making INTRODUCTION-1HR SDL
						Pharma (11pm -12pm) PH 1.19 Sedatives
12 PM- 1 PM	Pharma PH 1.18 Describe the MOA types and indications of General Anaesthetics	MI 4.1, 4.2, 4.3: Infective syndromes of skin, soft tissue, musculoskeletal systems	Patho PA 18.2 pathogenesis classification, features, hematologic features of acute leukemia Contd. SGD	MI 4.3: Staphylococcal infections	Patho PA 18.2 pathogenesis classification, features, hematologic features of chronic leukemia Contd. SGD	SDL Pharma 5 PH 1.22 Evaluate drugs of abuse

	Batch -1 (Micro)	Batch -1 (Pharma)	PA25.6	Batch -1 (Patho)	Pandemic 2.4 Vaccination
	MI 4.3, 8.15:	PH 3.5 Prepare and explain	Interpret liver	PA 16.6 peripheral blood	strategies including vaccine
	Anthrax, Leprosy,	a list of P-drugs for a given	function and viral	smear to identify	development &
	· • • ·	8 8	hepatitis serology		Implementation
201120	· · ·		1 07	5	1
	,		1 0		
	•				
			.,		
	staining-5				
			· · · · · · · · · · · · · · · · · · ·		
			5.14		
BATCH 2	Batch $2 - (Patho) PA$	Batch $2 - (Micro)$		Batch $2 - (Pharma)$	
Food items(cereals		× ,	PH 1.48		
,pulses,veg, oil nuts)		1 5	Antiviral drugs		
	0	MI 1.2: Gram staining-4	Ŭ		
				8	
				(DOAP)	
	SGD				
activity, physiological					
conditions					
	,pulses,veg, oil nuts) CM 5.1: Describe the common sources of various nutrients and special nutritional requirements according to age, sex, activity, physiological	BATCH 1 MI 4.3, 8.15: FM 14.9 MI 4.3, 8.15: REVISION CLASS FOR Anthrax,Leprosy, BONES Pseudomonas , Melioidosis, Actinomycetes,Nocar dia MI 1.2: Gram staining-5 MI 1.2: Gram staining-5 BATCH 2 Food items(cereals , pulses,veg, oil nuts) CM 5.1: Describe the common sources of various nutrients and special nutritional requirements according to age, sex, activity, physiological Batch 2 - (Patho) PA 19.1 causes and differentiating features of lymphadenopathy SGD	BATCH 1 FM 14.9MI 4.3, 8.15: Anthrax,Leprosy, Pseudomonas , Melioidosis, Actinomycetes,Nocar dia MI 1.2: Gram staining-5PH 3.5 Prepare and explain a list of P-drugs for a given case IV (DOAP)BATCH 2 Food items(cereals , pulses,veg, oil nuts) CM 5.1: Describe the common sources of various nutrients and special nutritional requirements according to age, sex, activity, physiologicalBatch 2 - (Patho) PA 19.1 causes and differentiating 	BATCH 1 FM 14.9MI 4.3, 8.15: Anthrax,Leprosy, Pseudomonas , Melioidosis, Actinomycetes,Nocar diaPH 3.5 Prepare and explain a list of P-drugs for a given case IV (DOAP)Interpret liver function and viral hepatitis serology panel. Distinguish obstructive from non-obstructive jaundice based on clinical features and liver functionBATCH 2 Food items(cereals pulses,veg, oil nuts)Batch 2 - (Patho) PA 19.1 causes and differentiating features of lymphadenopathy SGDBatch 2 - (Micro) MI 4.3: Leprosy MI 1.2: Gram staining-4Batch 2 - (Micro) MI 4.3: Leprosy MI 1.2: Gram staining-4PH 1.48 Antiviral drugs	BATCH 1 FM 14.9MI 4.3, 8.15: Anthrax,Leprosy, Pseudomonas, Melioidosis, Actinomycetes,Nocar diaPH 3.5 Prepare and explain a list of P-drugs for a given case IV (DOAP)Interpre liver function and viral hepatitis serology panel. Distinguish obstructive from non-obstructive jaundice based on clinical features and liver function tests IM 5.12, IMPA 16.6 peripheral blood smear to identify hemolytic anaemia from it DOAPBATCH 2 FOOd items(cereals pulses,veg, oil nuts) CM 5.1: Describe the common sources of various nutrients and special nutritional requirements according to age, sex, activity, physiologicalBatch 2 - (Patho) PA 19.1 causes and differentiating features of lymphadenopathyBatch 2 - (Micro) MI 4.3: Leprosy MI 1.2: Gram staining-4PH 1.48 Antiviral drugsBatch 2 - (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case IV (DOAP)

Time	9.8.2021	10.8.2021	11.8.2021	12.8.2021	13.8.2021	14.8.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.3 MECHANICAL INJURIES & WOUNDS - IV	Patho PA 19.2 pathogenesis and pathology of tuberculous lymphadenitis SGD	Pharma PH 1.19 Parkinsonism related drugs	Clinics Lecture OBGY OG6.1 Describe, discuss and demonstrate the clinical features of pregnancy, derive and discuss its differential	Clinics Lecture SURGERY SU 10.1 Describe the principles of perioperative management of common surgical procedures	MI 1.1: Overview of Viral infections and General Virology

				diagnosis, elaborate the principles underlying and interpret pregnancy tests.		
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.7: Bioethics continued: Case studies on autonomy and decision making SDL-2HRS Pharma (11pm -12pm) PH 1.19 Parkinsonism related drugs
12 PM- 1 PM	Pharma PH 1.19 Hypnotics	MI 4.1: Gas gangrene Tetanus (Clostridium tetani) Infections due to non- spring anaerobes	Patho PA 19.4pathogenesis, pathology and the differentiating features of Hodgkin's and non- Hodgkin's lymphoma PE 29.7, IM 4.5 SGD	MI 4.1 MI 4.3, 8.15 Infection due to non-fermeneters Actinomycetes and Nocardia	Patho PA 19.6 Enumerate and differentiate the causes of splenomegaly SGD	SDL Pathology PA32.1 Enumerate, classify and describe the etiology, pathogenesis, pathology and iodine dependency of thyroid swellings
2PM – 4PM	FMT PRACTICAL - BATCH 2 FM 14.9 REVISION CLASS FOR BONES	Batch -1 (Micro) MI 4.1, 4.3, 8.15: Staphylococcal, Streptococcal and Anaerobic infections MI 4.3, 8.15: SSTI due to Superficial and Subcutaneous fungal infections, Cutaneous and mucosal Candidiasis	Batch -1 (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case V (DOAP)	PA32.2 Describe the etiology, cause, iodine dependency, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis	Batch -1 (Patho) PA 19.1 causes and differentiating features of lymphadenopathy SGD	Pandemic 2.4 Vaccination strategies including vaccine development & Implementation

CM 5.1Describe the common sources of various nutrients and special	Batch 2 – (Patho) PA 19.3 describe features of tuberculous lymphadenitis in a gross and microscopic specimen DOAP	Batch 2 – (Micro) MI 4.3, 8.15: Anthrax,Leprosy, Pseudomonas , Melioidosis, Actinomycetes,Nocardia MI 1.2: Gram staining-5	PH 1.36 Describe the MOA doses and indications of anti thyroid drugs	Batch 2 – (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case V (DOAP)	
---	---	--	--	--	--

Time	16.8.2021	17.8.2021	18.8.2021	19.8.2021	20.8.2021	21.8.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM8.3 Enumerate and describe disease specific National Health Programs including their prevention and treatment of a case (Malaria)	Patho PA 21.1 Describe normal hemostasis SDL	Pharma PH 1.19 Anti epileptic drugs II	Holiday	Clinics Lecture SURGERY SU 12.1 Enumerate the causes and consequences of malnutrition in the surgical patient SU 12.2 Describe and discuss the methods of estimation and replacement of the fluid and electrolyte requirements in the surgical patient SU 12.3 Discuss the nutritional requirements of surgical patients, the methods of providing nutritional support and their complications	MI 1.1: Overview of Viral infections and General Virology
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting		Clinical Posting	AETCOM (9-11) Module 2.7: Bioethics continued: Case studies on autonomy and decision

					making Anchoring lecture - 1 hour iv. Discussion and closure of case - 1 hour Pharma (11pm -12pm) PH 1.19 Anti Depressants
12 PM- 1 PM	Pharma PH 1.19 Anti epileptic drugs I	MI 4.3 Viral exanthems 1	Patho PA21.2, pathogenesis and pathologyITP and haemophilia's SGD PE 29.6, PE 29.7	Patho PA 21.4 disseminated intravascular coagulation, laboratory findings and diagnosis SGD	MI 5.2 Viral agents of encephalitis-1: Rabies and HSV encephalitis
2PM – 4PM	FMT PRACTICAL - BATCH 1 FM 14.4 AGE ESTIMATION FROM X-RAY (SHOULDER / ELBOW / WRIST) Batch 2 Food items (Fish, egg,meat,milk, fruits)	Batch -1 (Micro) MI 5.1: Agents of aseptic meningitis-1 MI 5.3, 8.15: Agents of pyogenic meningitis	Batch -1 (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case VI (DOAP)	Batch -1 (Patho)PA 19.3 describe features of tuberculous lymphadenitis in a gross and microscopic specimen DOAP	Pandemic 2.4 Vaccination strategies including vaccine development & Implementation
	CM 5.1 Describe the common sources of various nutrients and special nutritional requirements according to age, sex, activity, physiological conditions	Batch 2 – (Patho) PA 19.5 features of Hodgkin's lymphoma in gross and microscopic specimen PA 19.7 gross specimen of an enlarged spleen DOAP	Batch 2 – (Micro) MI 4.1, 4.3, 8.15: Staphylococcal, Streptococcal and Anaerobic infections MI 4.3, 8.15: SSTI due to Superficial and Subcutaneous fungal infections, Cutaneous and mucosal Candidiasis	Batch 2 – (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case VI (DOAP)	

Time	23.8.2021	24.8.2021	25.8.2021	26.8.2021	27.8.2021	28.8.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.4 MEDICO-LEGAL ASPECTS OF INJURIES - I	Patho PA 21.5Define and describe disseminated intravascular coagulationand diagnosis of Vitamin K deficiency SGD PE 12.13 PE 12.14	Pharma PH 1.19 drugs on Schizophrenia	Clinics Lecture OBGY OG7.1 Describe and discuss the changes in the genital tract, cardiovascular system, respiratory, haematology, renal and gastrointestinal system in pregnancy. (part 1)	Clinics Lecture SURGERY SU 13.1 Describe the immunological basis of organ transplantation SU 13.2 Discuss the Principles of immunosuppressive therapy. Enumerate Indications, describe surgical principles, management of organ transplantation SU 13.3 Discuss the legal and ethical issues concerning organ donation	MI: 1.1: Overview of parasitic infections and General Parasitology
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.8: What does it mean to be family member of a sick patient? Hospital visit & interviews - 2 hours Pharma (11pm -12pm) PH 1.19 Opioid drugs I

12 PM- 1 PM	Pharma PH 1.19 DRugs used for Bipolar Disease	MI 4.3 Viral exanthems 2	Patho PA 22.1Classify and describe blood group systems (ABO and RH) FM 14.8 DOAP	MI 4.3 Tissue nematode infections of skin and soft-tissue	Patho PA22.4 Enumerate blood components and describe their clinical uses SU3.1 OG10.2, IM 9.18, IM 15.12 AS 9.4	Sports
2PM – 4PM	FMT PRACTICAL - BATCH 2 FM 14.4 AGE ESTIMATION FROM X-RAY (SHOULDER / ELBOW / WRIST)	Batch -1 (Micro) MI 5.1: Agents of aseptic meningitis-2 MI 5.2, 8.15: Aseptic meningitis	Batch -1 (Pharma) PH 3.4 Recognize and report an adverse drug reaction I (SGD 5)	PA32.3 Describe the etiology, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis/ hypothyroidism IM22.2 IM 12.1, IM 12.2 PH 1.36 Anti Thyroid drugs	Batch -1 (Patho)PA 19.5 features of Hodgkin's lymphoma in gross and microscopic specimen PA 19.7 gross specimen of an enlarged spleen DOAP	
	CM practical batch 1 Food items (Fish,egg,meat,milk) CM 5.1 Describe the common sources of various nutrients and special nutritional requirements according to age, sex, activity, physiological conditions	Batch 2 – (Patho) PA 20.1Describe the features of plasma cell myeloma DOAP	Batch 2 – (Micro) MI 5.1: Agents of aseptic meningitis-1 MI 5.3, 8.15: Agents of pyogenic meningitis		Batch 2 – (Pharma) PH 3.4 Recognize and report an adverse drug reaction I (SGD 6)	

Time	30.8.2021	31.8.2021	1.9.2021	2.9.2021	3.9.2021	4.9.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday

8 AM-9 AM	CM8.1 Describe and discuss the epidemiological and control measures including the use of essential laboratory tests at the primary care level for communicable diseases (Leprosy)	Patho PA22.5 Enumerate and describe infections transmitted by blood transfusion SGD	Pharma PH 1.34 Anti emetics	Clinics Lecture MEDICINE IM9.17 Describe the indications for blood transfusion and the appropriate use of blood components IM9.18 Describe the precautions required necessary when performing a blood transfusion	Clinics Lecture OBGY OG7.1 Describe and discuss the changes in the genital tract, cardiovascular system, respiratory, haematology, renal and gastrointestinal system in pregnancy. (part2)	MI 1.8: Components of Immune System-Organs, cells and products
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.8: What does it mean to be family member of a sick patient? Large Group Discussions with patients' relatives - 1 hour Pharma (11pm -12pm) PH 1.36 Diabetes Mellitus I
12 PM- 1 PM	Pharma PH 1.19 Opioid drugs II	MI 5.1 Superficial Subcutaneous fungal infections, Candidiasis P marneffei	Patho PA 22.6Describe transfusion reactions and enumerate the steps in the investigation of a transfusion reaction SDL	MI 5.1: Infective syndromes of CNS	Patho PA 22.7Enumerate the indications and describe the principles and procedure of autologous transfusion	SDL Pharma 6 PH 1.23 Describe the process of drug de-addiction
2PM – 4PM	FMT PRACTICAL - BATCH 1 FM 14.4 AGE ESTIMATION FROM X-RAY (PELVIS)	Batch -1 (Micro) MI 6.2: URTI Throat swab Gram staining-1,2,3 and certification	Batch -1 (Pharma) PH 3.4 Recognize and report an adverse drug reaction II	PA24.2 Describe the etiology, pathogenesis, pathology, microbiology,	Batch -1 (Patho) PA 20.1Describe the features of plasma cell myeloma DOAP	

CM practical Batch 2 Drugs leprosy, malaria	Batch 2 – (Patho) PA 23.2 abnormal urinary findings in disease states,common urinary abnormalities in a clinical specimen PE 21.11 DOAP	Batch 2 – (Micro) MI 5.1: Agents of aseptic meningitis-2 MI 5.2, 8.15: Aseptic meningitis	clinical and microscopic features of peptic ulcer disease IM15.1,MI 3.6 PH 1.34 Drugs used in Peptic Ulcer disease	Batch 2 – (Pharma) PH 3.4 Recognize and report an adverse drug reaction II	
	DOAP		Ulcer disease		

Time	6.9.2021	7.9.2021	8.9.2021	9.9.2021	10.9.2021	11.9.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.4 MEDICO-LEGAL ASPECTS OF INJURIES - II	Patho PA 23.2Describe abnormal findings in body fluids in various disease statesIM17.7,IM 17.9, MI5.1	Pharma PH 1.41 Drugs used in infertility/erectile dysfunction	Clinics Lecture MEDICINE IM11.1 Define and classify diabetes IM11.4 Describe and discuss the genetic background and the influence of the environment on diabetes	Clinics Lecture OBGY OG7.1 Describe and discuss the changes in the genital tract, cardiovascular system, respiratory, haematology, renal and gastrointestinal system in pregnancy(part 3)	MI 5.2: Viral agents of encephalitis-2
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.8: What does it mean to be family member of a sick patient? SDL-2hr Pharma (11pm -12pm) PH 1.40, Tocolytics (SGD 8)

12 PM- 1 PM	Pharma PH 1.36 Diabetes Mellitus II	MI 5.1 Agents of pyogenic meningitis	Path PA 22.2(Patho)enumerate,dem onstrate the steps of compatibility testing PA 16.7Describe the correct	MI 5.2 Viral agents of encephalitis-2: Arboviral encephalitis (JE	PA24.1 Describe the etiology, pathogenesis, pathology and clinical features of oral cancers DE 4.1. DE	SDL Patho PA 21.3 Differentiate platelet from clotting disorders based on the clinical and hematologic features
			technique to perform a cross match SGD o IM15.13	and Westnile), Nipah virus infection, Slow viral infections	4.2, DE 4.3 SGD	
2PM – 4PM	FM TPRACTICAL - BATCH 2 FM 14.4 AGE ESTIMATION FROM X-RAY (PELVIS)	Batch -1 (Micro) MI 6.3: Sputum Gram staining-1,2,3 and certification	Batch -1 (Pharma) PH 3.4 Recognize and report an adverse drug reaction III	PA24.3 Describe and identify the microscopic features of peptic ulcer IM 15.2, IM 15.3, IM 15.9, IM 15.11 PH 1.34 Describe the MOA doses of	Batch -1 (Patho) PA 23.2 abnormal urinary findings in disease states,common urinary abnormalities in a clinical specimen PE 21.11 DOAP	
	CM practical batch 1 drugs leprosy malaria	Batch 2 – PA 23.3Describe and interpret the abnormalities in semen analysis, thyroid function tests, renal function tests ,liver function tests DOAP	Batch 2 – (Micro) Batch -1 (Micro) MI 6.2: URTI Throat swab Gram staining-1,2,3 and certification	drugs in GERD	Batch 2 – (Pharma) PH 3.4 Recognize and report an adverse drug reaction III	

Time 1	13.9.2021	14.9.2021	15.9.2021	16.9.2021	17.9.2021	18.9.2021

	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM Leprosy national health programe 8.3 Enumerate and describe disease specific National Health Programs including their prevention and treatment of a case (Leprosy)	PA24.5 pathogenesis and pathologic features of Tuberculosis of the intestine PA24.6 pathogenesis and pathologic and distinguishing features of Inflammatory bowel disease IM 16.15	Pharma PH 1.37 Describe the MOA types and indications of drugs (ant. pituitary hormones)	Clinics Lecture MEDICINE IM11.2 Describe and discuss the epidemiology and pathogenesis and risk factors and clinical evolution of type 1 diabetes	Clinics Lecture OBGY OG8.1 Enumerate, describe and discuss the objectives of antenatal care, assessment of period of gestation; screening for high-risk factors. (part1)	MI 8.8: Environmental surveillance (bacteriology of water, air, milk and surface)
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.8: What does it mean to be family member of a sick patient? Discussion and closure - 1 hour Pharma (11pm -12pm) PH 1.38 Evaluate the indications, C/I and S/E of corticosteroids

			~			6777 X 61
12 PM-	Pharma	MI 5.2: Parasites	PA24.7	MI 4.1,1.1	PA29.1	SDL Micro
1 PM	Ph 1.38	causing encephalitis	Describe the etiology,	Tetanus, botulism	Classify and	MI 6.1
	Describe the MOA,		pathogenesis, pathology	Neurocysticercosis	pathogenesis of	Bacterial URTI
	types and doses of		and distinguishing features		testicular tumors	
	Corticosteroids		of carcinoma of the colon		PA 29.2carcinoma of the	
			PA 24.4 carcinoma		penis	
			stomach			
2PM -	FMT Practicals	Batch -1 (Micro)	Batch -1 (Pharma)	PA24.4	Batch -1 (Patho)	
4PM	Batch 1	MI 6.3, 1.2:	PH 3.4 Recognize and	Describe and	PA 23.3Describe and	
41 101	FM 14.4	Laboratory diagnosis	report an adverse drug	etiology and	interpret the	
	AGE ESTIMATION	of tuberculosis and	reaction IV	pathogenesis and	abnormalities in semen	
			reaction IV			
	FROM LOWER	Acid fast staining-5		pathologic features	analysis, thyroid function	
	LIMB BONES	MI 6.3: Sputum Acid		of carcinoma of the	tests, renal function tests	
		fast staining and		stomach	,liver function tests	
		certification			DOAP	
	Batch 2:	Batch 2 – (Patho)	Batch 2 – (Micro)		Batch 2 – (Pharma)	
	CM practical	PA24.5,24.6,24.7	MI 6.3: Sputum Gram		PH 3.4 Recognize and	
	Drugs ARI,	DOAP	staining-1,2,3 and		report an adverse drug	
	Diarrhoea		certification		reaction IV	

Time	20.9.2021	21.9.2021	22.9.2021	23.9.2021	24.9.2021	25.9.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday

8 AM-9 AM	FM 3.4 MEDICO-LEGAL ASPECTS OF INJURY - III	PA29.3 AND PA29.5 benign prostatic hyperplasia SDL	Pharma Ph 1.39 Female gonadal hormones Drugs used in infertility	Clinics Lecture MEDICINE IM11.3 Describe and discuss the epidemiology and pathogenesis and risk factors economic impact and clinical evolution of type 2 diabetes	Clinics Lecture OBGY OG8.1 Enumerate, describe and discuss the objectives of antenatal care, assessment of period of gestation; screening for high-risk factors. (part 2)	MI 1.6: Antimicrobial stewardship and Rational use of antimicrobial agents
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Pandemic 2.5 Therapeutic strategies including new drug development (9 am-11am) Pharma (11pm -12pm) Ph 1.39 Drugs used for contraception
12 PM- 1 PM	Pharma PH 1.36 Drugs for Osteoporosis	MI 6.1 Normal commensals and defense mechanisms Infective syndrome of respiratory system	PA26.1 Define and describe the etiology, types, pathogenesis, stages, morphology and complications of pneumonia PA26.2 lung abscess	MI 6.1 Viral URTI-1	PA26.5 Occupational lung disease PA26.6, PA 26.7 tumors of the lung and pleura, mesothelioma	Sports
2PM – 4PM	FMT Practicals Batch 2 FM 14.4 AGE ESTIMATION FROM LOWER LIMB BONES	Batch -1 (Micro) MI 6.1, Fungal agents, Parasitic agents MI 6.3 LRTI	Batch -1 (Pharma) PH 3.6, PH 3.7 List of essential medicines/ optimized interaction with PR for drug information (SGD 7)	PA 29.4 Describe the pathogenesis, pathology, hormonal dependency	Batch -1 (Patho) PA24.5,24.6,24.7 DOAP	

Batch 1: CM practical Drugs ARI, Diarrhoea	PA24.5,24.6,24.7 DOAP	Batch -1 (Micro) MI 6.3, 1.2: Laboratory diagnosis of tuberculosis and Acid fast staining-5 MI 6.3: Sputum Acid fast staining and certification	presenting and distinguishing features, diagnostic tests, progression and spread of carcinoma of the prostate	Batch 2 – (Pharma) PH 3.6, PH 3.7 List of essential medicines/ optimized interaction with PR for drug information (SGD 8)	
---	--------------------------	--	---	--	--

Time	27.9.2021	28.9.2021	29.9.2021	30.9.2021	1.10.2021	2.10.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM						
9 AM- 12 PM			Internal asso	essment		
12 PM- 1 PM						
2PM – 4PM						

Time	4.10.2021	4.10.2021	6.10.2021	7.10.2021	8.10.2021	9.10.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM						
9 AM- 12 PM			Internal asse	essment		
12 PM- 1 PM						
2PM – 4PM						

DEAN

Time	11.10.2021	12.10.2021	13.10.2021 HOLIDAY	14.10.2021	15.10.2021	16.10.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM 8.1 Describe and discuss the epidemiological and control measures including the use of essential laboratory tests at the primary care level for communicable diseases(ARI)	PA27.1 arteriosclerosis PA 27.2 aneurysms SGD	HOLIDAY	Clinics Lecture MEDICINE IM11.5 Describe and discuss the pathogenesis and temporal evolution of microvascular and macrovascular complications of diabetes	HOLIDAY	MI 1.1: Overview of bacterial infections and Bacterial Taxonomy
9 AM- 12 PM	Clinical Posting	Clinical Posting		Clinical Posting		PA27.5 Describe the epidemiology, risk factors, etiology, pathophysiology, pathology, presentations, gross and microscopic features, diagnostic tests and complications of IHD SGD Pandemic 2.5 Therapeutic strategies including new drug development (10 am-11 am) Pharma (11pm -12pm) 1.43 Discuss the use of antimicrobials
12 PM- 1 PM	Pharma PH 1.42 Describe Principles of Antimicrobial chemotherapy	MI 6.1: Viral URTI- 2, Fungal URTI:		MI 6.1: Agents of typical pneumonia		SDL Pharma 7 PH 1.58 Describe drugs used in skin disorders

2PM - 4PM	FMT Practicals Batch 1 FM 14.4 AGE ESTIMATION FROM SKULL BONE	Batch -1 (Micro) MI 7.3: SGD, Agents of UTI Practical on UTI	PA27.4Define and describe the etiology, types, pathogenesis, stages, morphology microscopic appearance and complications of tuberculosis	sports
	CM batch 2 SDL; Growth chart	Batch 2 – (Patho) PA26.3 ,pathogenesis, stages, morphology and complications and evaluation of Obstructive airway disease (OAD) and bronchiectasis SGD	PH 1.44 Pharmacotherapy for tuberculosis	

Time	18.10.2021	19.20.2021 HOLIDAY	20.10.2021	21.10.2021	22.10.2021	23.10.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.5 GRIEVOUS HURT	HOLIDAY	Pharma PH 1.43 Describe the MOA, doses, indications, S/E of Cephalosporins	Clinics Lecture MEDICINE IM11.6 Describe and discuss the pathogenesis and precipitating factors, recognition and management of diabetic emergencies	Clinics Lecture SURGERY SU 4.2 Describe Surgical approaches, incisions and the use of appropriate instruments in Surgery in general SU 4.3 Describe the materials and methods used for surgical wound closure and anastomosis [sutures, knots and needles]	MI 1.1: Overview of bacterial infections and Bacterial Taxonomy

9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Patho PA27.10 syphilis on the cardiovascular system PA 27.9 Cardiomyopathies SGD Pharma (11pm -12pm) PH 1.43 Describe the MOA, doses, indications, S/E of Monobactams
12 PM- 1 PM	Pharma PH1.43 Describe the MOA, doses, indications, S/E of beta lactams	PA27.6 infective endocarditis PA 27.7 pericardial effusion SGD	MI 6.1: Tuberculosis & NTM Integrated with Patho, Medicine	PA 28.2 renal failure PA28.4 chronic renal failure SGD	SDL Patho PA28.1 Describe the normal histology of the kidney
2PM – 4PM	FMT Practicals Batch 2 FM 14.4 AGE ESTIMATION FROM SKULL BONE	Batch -1 (Pharma) PH 5.1, 5.2 Communicate with the patient with empathy and ethics , optimal use of drug therapy/devices (SGD 9)	PA27.4 Describe the etiology, pathophysiology, pathology, gross and microscopic features, criteria and complications	Batch 1 PA26.3 pathogenesis, evaluation of Obstructive airway disease (OAD) and bronchiectasis SGD	sports
	CM SDL Batch 1 Growth chart	Batch -1 (Micro) MI 6.1, Fungal agents, Parasitic agents MI 6.3 LRTI	of rheumatic fever PH 1.43 Prophylaxis of rheumatic fever	Batch 2 – (Pharma) PH 5.1,5.2 Communicate with the patient with empathy and ethics of drug use, optimal use of drug therapy/devices (SGD 10)	

		Time	25.10.2021	26.10.2021	27.10.2021	28.10.2021	29.10.2021	30.10.2021
--	--	------	------------	------------	------------	------------	------------	------------

	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM Diarrhoea (IMNCI)	PA28.6,PA28.7 IgA nephropathy , glomerular manifestation of systemic disease SGD	Pharma PH 1.43 Describe the MOA, doses, indications, S/E of Aminoglycosides II	Clinics Lecture MEDICINE IM12.1 Describe the epidemiology and pathogenesis of hypothyroidism and hyperthyroidism including the influence of iodine deficiency and autoimmunity in the pathogenesis of thyroid disease	Clinics Lecture SURGERY SU 14.1 Describe Aseptic techniques, sterilization and disinfection	MI 1.1: Overview of bacterial infections and Bacterial Taxonomy
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	PA28.8 diseases affecting the tubular interstitium PA 28.9 acute tubular necrosis SGD Pharma (11pm -12pm) PH1.43 Describe the MOA, doses, indications, S/E of Sulfonamides, tetracyclines,Cotrimoxazole
12 PM- 1 PM	Pharma PH 1.43 Describe the MOA, doses, indications, S/E of Aminoglycosides I	MI 6.1: Tuberculosis & NTM Integrated with Patho, Medicine	PA28.12 cystic disease of the kidney SGD	MI 6.1: Agents of atypical pneumonia(Bacter ial)	PA28.14 renal tumours SGD	Pandemic 2.5 Therapeutic strategies including new drug development
2PM – 4PM	FMT Practicals Batch 2 FM 14.1 PREPARATION OF INJURY REPORT	Batch -1 (Micro) MI 1.2: Stool microscopy-5	Batch -1 (Pharma) PH 5.3, 5.4 Motivate patients with chronic disease to adhere to the prescribed management,cost management and compliance (SGD 11)	PA 28.13 renal stone disease , obstructive uropathy PH 1.48 Describe the MOA, doses, S/E	Batch -1 (Patho) PA27.3 Describe the etiology, types, stages pathophysiology, pathology and complications of heart failure SGD	sports

			of drugs used in UTI (SGD 13)		
CM SDL 2 batch 1 Define and describe the concept of geriatric services.	Batch 2 – (Patho) PA27.3 Describe the etiology, types, stages pathophysiology, pathology and complications of heart failure SGD	Batch 2 – (Micro) Batch -1 (Micro) MI 7.3: SGD, Agents of UTI Practical on UTI		Batch 2 – (Pharma) PH 5.3, 5.4 Motivate patients with chronic disease to adhere to the prescribed management,cost management and compliance (SGD 12)	

Time	1.11.2021	2.11.2021	3.11.2021	4.11.2021	5.11.2021	6.11.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.6 PATHOLOGY & HEALING OF INJURIES	PA28.11 vascular disease of the kidney	Pharma PH1.43 Describe the MOA, doses, indications, S/E of Fluroquinolones, misc		Clinics Lecture SURGERY SU 15.1 Describe classification of hospital waste and appropriate methods of disposal	MI 7.3: Normal commensals of genitourinary tract Urinary tract infections
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting		Clinical Posting	PA28.15 thrombotic angiopathies SGD

				HOLIDAY		Pharma (11pm -12pm) PH 1.44 Describe the MOA, doses, S/E of antitubercular drugs
12 PM- 1 PM	Pharma PH1.43 Describe the MOA, doses, indications, S/E of Macrolides and lincosamides	MI 6.1: Viral agents of LRTI	PA30.1 Describe the epidemiology, pathogenesis, etiology, pathology,screening, diagnosis and progression of carcinoma of the cervix SGD		PA30.2 carcinoma endometrium PA 30.3 leiomyoma leiomyosarcoma SGD	Clinics Lecture SURGERY SU 18.1 Describe the pathogenesis, clinical features and management of various cutaneous and submucous infections
2PM – 4PM	FMT Practicals Batch 1 FM 14.1 PREPARATION OF INJURY REPORT	Batch -1 (Micro) MI 7.1, 7.2: Practical on STI	Batch -1 (Pharma) PH 5.5, 5.6 Educate patients regarding drug dependence and OTC drugs (SGD 13)		Batch -1 (Patho) PA27.8 Interpret abnormalities in cardiac function testing in acute coronary syndromes DOAP	Sports
	M BATCH 2 Define and describe the concept of geriatric services	Batch 2 – (Patho) PA27.8 Interpret abnormalities in cardiac function testing in acute coronary syndromes DOAP	Batch 2 – (Micro) MI 1.2: Stool microscopy- 5		Batch 2 – (Pharma) PH 5.5, 5.6 Educate patients regarding drug dependence and OTC drugs (SGD 14)	

Time	8.11.2021	9.11.2021	10.11.2021	11.11.2021	12.11.2021	13.11.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday

8 AM-9 AM	FM 3.7 INJURY AS CAUSE OF DEATH & CERTIFICATION	PA 30.5 gestational trophoblastic neoplasms	Pharma PH1.55 Describe the MOA, doses, S/E of Leprosy drugs	Clinics Lecture OBGY OG9.4 Discuss the clinical features, laboratory investigations, ultrasonography, differential diagnosis, principles of management and follow up of gestational trophoblastic neoplasms	Clinics Lecture SURGERY SU 16.1 Minimally invasive General Surgery. Describe indications, advantages and disadvantages of Minimally Invasive General Surgery	MI 8.5, MI 8.6: Hospital acquired infections
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	PA 30.6 cervicitis PA 30.7 endometriosis SGD Pharma (11pm -12pm) PH 1.47 Describe the MOA, doses, S/E of drugs used in malaria and kala azar
12 PM- 1 PM	Pharma PH 1.45, PH 1.46 Describe the MOA, doses, S/E of XDR and MDR TB	MI 7.1, 7.2: Sexually transmitted infections	PA 30.8 adenomyosis PA 30.9 endometrial hyperplasis	MI 7.2:Agents of genital ulcers-1- Syphilis MicAgents of vaginal drge Lectureischa	PA 31.2, PA 31.3 carcinoma breast SGD	SDL Pharma 8 PH 1.63 Discuss pediatric and geriatric pharmacology
2PM – 4PM	FMT Practical Batch 2 FM 14.10 INJURY REPORT REVISION	Batch -1 (Micro) MI 8.11: Demonstrate respect for patient samples sent for lab investigations	Batch -1 (Pharma) PH 5.7 Demonstrate an understanding of legal and ethical aspects of prescribing drugs	PA28.3 Define and describe the etiology, precipitating factors,	Batch -1 (Patho) PA 31.1 benign breast disease PA 31.4 gynaecomatia SGD	Pandemic 2.5 Therapeutic strategies including new drug development

A			pathogenesis, pathology, laboratory urinary findings,		Formatted: Highl
CM:BATCH 1 SDL DEFINE AND DESCRIBE THE CONCEPT OF INTERNATIONAL HEALTH	Batch 2 – (Patho) PA 31.1 benign breast disease PA 31.4 gynaecomatia SGD	Batch 2 – (Micro) MI 7.1, 7.2: Practical on STI	progression and complications of acute renal failure	Batch 2 – (Pharma) PH 5.7 Demonstrate an understanding of legal and ethical aspects of prescribing drugs	

Time	15.11.2021	16.11.2021	17.11.2021	18.11.2021	19.11.2021	20.11.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM CM 8.1: Describe and discuss the epidemiological and control measures including the use of essential laboratory tests at the primary care level for communicable diseases (Diarrhoea)	Patho PA 32.5 hyperparathyroidism	Pharma PH 1.55 Drugs for intestinal helminthiasis	Clinics Lecture OBGY OG10.2 Enumerate the indications and describe the appropriate use of blood and blood products, their complications and management.	HOLIDAY	MI 3.1: Intestinal nematodes- Ascaris, hookworm, Trichuris, Enterobius and Strongyloides

9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	PA 32.6 metastasis of pancreatic cancer Pharma (11pm -12pm) PH 1.48 Describe the MOA, doses, S/E of drugs used in HIV
12 PM- 1 PM	Pharma PH 1.48 Describe the MOA, doses, S/E of drugs used in HIV	MI 8.8: Environmental surveillance	PA 32.7 adrenal insufficiency	MI 1.6: Antimicrobial stewardship	SDLPatho PA 32.8 cushing's syndrome
2PM – 4PM	Batch 1MI 8.12PH 3.1FM 14.10Confidentialityeffection	Batch -1 (Pharma) PH 3.8 communicate effectively with patients on proper use of medication	PA28.5 Define and classify glomerular diseases. Enumerate and describe the etiology, pathogenesis, mechanisms of glomerular injury, pathology,	sports	
	CM:BATCH 2 SDL DEFINE AND DESCRIBE THE CONCEPT OF INTERNATIONAL HEALTH	Batch 2 – (Patho) PA 32.9 adrenal neoplasm SGD	Batch 2 – (Micro) MI 8.11: Demonstrate respect for patient samples sent for lab investigations	pathology, distinguishing features and clinical manifestations of glomerulonephritis	

Time	22.11.2021	23.11.2021	24.11.2021	25.11.2021	26.11.2021	27.11.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.8 DIFFERENT TYPES OF WEAPONS, DANGEROUS WEAPONS.	PA 33.1 osteomyelitis	Pharma PH 1.47 Drugs for amoebiasis and antidiarrheal	Clinics Lecture OBGY OG8.8 Enumerate the indications and describe the investigations including the use of ultrasound in the initial assessment and monitoring in pregnancy	Clinics Lecture SURGERY SU 17.3 Describe the Principles in management of mass casualties	MI 1.1: Infective syndrmes of ear, nose and oral cavity (in brief)
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Patho PA 33.2 bone tumours SGD Pharma (11pm -12pm) PH 1.55 Drugs for filariasis
12 PM- 1 PM	Pharma PH1.43 Drugs used for fungal infection	MI 1.1: Infective syndrmes of eye	PA 33.3 soft tissue tumours SGD	MI 1.1: Infective syndrmes of ear, nose and oral cavity	PA 33.4 Paget's disease of bone SGD	Clinical lecture SURGERY SU 18.2 Classify skin tumours Differentiate different skin tumours and discuss their management

2PM –	FMT Practical	Batch -1 (Micro)	Batch -1 (Pharma)	PA28.10	Batch -1 (Patho)	sports
4PM	Batch 2	MI 8.14	PH 3.8 communicate	pathogenesis,	PA 32.9 adrenal	
	FM 14.11 WEAPON	Demonstrate	effectively with patients on	pathology,	neoplasm SGD	
	EXAMINATION 1	confidentiality	proper use of medication	laboratory Human	-	
		pertaining to patient's	(SGD 15)	Anatomy findings,		
		identity		distinguishing		
		in lab result		features		
	A			progression and		
	CM Batch 1Describe	Batch 2 – (Patho)	Batch 2 – (Micro)	complications of	Batch 2 – (Pharma)	
	food hygiene	PA 33.5 rheumatoid	MI 8.12	acute and chronic	PH 3.8 communicate	
	50	arthritis SGD	Confidentiality pertaining	pyelonephritis and	effectively with patients	
			to patient's identity in lab	reflux nephropathy	on proper use of	
			result		medication (SGD16)	

Formatted: Highlight

Time	29.11.2021	30.11.2021	1.12.2021	2.12.2021	3.12.2021	4.12.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM 8.3 Enumerate and describe disease specific National Health Programs including their prevention and treatment of a case (IMNCI-Diarrhoea)	Patho PA34.1 squamous cell carcinoma skin SGD	Pharma PH 1.49 Drugs used for Cancer therapy	Clinics Lecture MEDICINE IM12.2 Describe and discuss the genetic basis of some forms of thyroid dysfunction	Clinics Lecture OBGY OG9.1 Classify, define and discuses the aetiology and management of abortions including threatened, incomplete, inevitable, missed and septic (part 1)	MI 3.8: Organisms of oncogenic potential

9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Patho PA 34.2 basal cell carcinoma skin SGD
						Pharma (11pm -12pm) PH 1.54 Describe the vaccines and their uses
12 PM- 1 PM	Pharma PH 1.49 Principles of Anticancer therapy	MI 8.1: Zoonotic infections Congenital infections	Patho PA 34.3 melanoma skin	MI 8.2: Opportunistic infections Transplant infections	Clinics Lecture MEDICINE IM11.1 Define and classify diabetes	Clinical lecture OBGY OG9.1 Classify, define and discuses the aetiology and management of abortions including threatened, incomplete, inevitable, missed and septic. (part2)
2PM – 4PM	FMT Practical Batch 1 FM 14.11 WEAPON EXAMINATION 1	Batch -1 (Micro) MI 8.14: Demonstrate confidentiality pertaining to patient's identity in lab result	Batch -1 (Pharma) PH 3.2 Perform and interpret critical audit of prescription (DOAP)	PA28.16 Describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of urothelial tumors	Batch -1 (Patho)PA 33.5 rheumatoid arthritis SGD	Sports
	CM Batch 2Describe food hygiene	Batch 2 – (Patho) PA 33.5 rheumatoid arthritis contdSGD	Batch -2 (Micro) MI 8.14: Demonstrate confidentiality pertaining to patient's identity in lab result	PH 1.49 Cancer chemotherapy	Batch 2 – (Pharma) PH 3.2 Perform and interpret critical audit of prescription (DOAP)	

DEAN

Time	6.12.2021	7.12.2021	8.12.2021	9.12.2021	10.12.2021	11.12.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FMT SDL IDENTIFICATION CASE STUDY	PA 35.1Describe the etiology, types and pathogenesis, differentiating factors, CSF findings in meningitis	Pharma PH 1.62 Antiseptic disinfectants (SDL 10)	Clinics Lecture MEDICINE IM12.3 Describe and discuss the physiology of the hypothalamopituita ry - thyroid axis, principles of thyroid function testing and alterations in physiologic function IM12.4 Describe and discuss the principles of radio iodine uptake in the diagnosis of thyroid disorders	Clinics Lecture OBGY OG9.3 Discuss the aetiology, clinical features, differential diagnosis of acute abdomen in early pregnancy (with a focus on ectopic pregnancy) and enumerate the principles of medical and surgical management	MI 3.7: Hepatobilliary infective syndrome
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	PA 35.1Describe the etiology, types and pathogenesis, differentiating factors, CSF findings in meningitis SGD
						11-12 AM- Pharma PH 1.52 Describe Management of common poisoning (SGD 15)

12 PM- 1 PM	Pharma PH 1.53 Describe the heavy metal poisoning and chelating agents	MI 8.3: Organisms of oncogenic potential	PA 35.2Classify and describe the etiology, genetics, pathogenesis, pathology, presentation sequelae and complications of CNS tumors	MI 8.4: Emerging and Re-emerging Infections Microbial agents of Bioterrorism	PathoPA36.1Describe the etiology, genetics, pathogenesis, pathology, presentation, sequelae and complications of retinoblastoma	SDL Pharma 9 PH 3.3 Critically evaluate Package insert
2PM – 4PM	FMT SDL Batch 2 INJURY CASE STUDY	Batch -1 (Micro) MI 1.1: Lab diag of viral inf, micro, culture	Batch -1 (Pharma) PH 3.2 Perform and interpret critical audit of prescription	PA30.4 Classify and describe the etiology, pathogenesis, pathology, morphology,	Batch -1 (Patho) PA 35.31dentify the etiology of meningitis based on given CSF parameters DOAP	sports
	CM Batch 1:describe the concept of essential Medicine	Batch 2 – (Patho) PA 35.3Identify the etiology of meningitis based on given CSF parameters DOAP	Batch 2 – (Micro) MI 1.1: Lab diag of viral inf, micro, culture	clinical course, spread and complications of ovarian tumors	Batch 2 – (Pharma) PH 3.2 Perform and interpret critical audit of prescription	

Formatted: Highlight

Time	13.12.2021	14.12.2021	15.12.2021	16.12.2021	17.12.2021	18.12.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9	СМ	Clinics Lecture	Pharma	Clinics Lecture	Clinics Lecture	MI 8.16: National health
AM	CM8.4 Describe the	MEDICINE	PH 1.34	MEDICINE	OBGY	programs
	principles and	IM13.1 Describe the	Purgatives and laxatives	IM4.1 Describe and	OG9.5 Describe the	Integrated with CMMI 8.16:
	enumerate the	clinical epidemiology	(SDL12)	discuss the febrile	etiopathology, impact on	National health programs
	measures to control a	and inherited &		response and the	maternal and fetal	Integrated with CM

	disease epidemic	modifiable risk factors for common malignancies in India		influence of host immune status, risk factors and comorbidities on the febrile response IM4.2 Describe and discuss the influence of special populations on the febrile response including: the elderly, immune suppression, malignancy and	health and principles of management of hyperemesis gravidarum	
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting		Clinical Posting	Clinics Lecture MEDICINE IM15.1 Enumerate, describe and discuss the aetiology of upper and lower GI bleeding Pharma (11pm -12pm) PH 1.63 describe drug regulation acts and other legal aspects
12 PM- 1 PM	Pharma PH 1.57 Describe drugs used in ocular diseases (SDL 11)	MI 1.1: Vector-borne infections Laboratory acquired infections	FMT SDL INJURY CASE STUDY 2	MI 8.13: Choose appropriate labaratory test in diagnosis of infectious disease (Rational use of microbiological investigations)	FMT SDL IDENTIFICATION CASE STUDY	SDL PA 29.1 Testicular tumours revision

2PM – 4PM	FMT SDL Batch 1 INJURY CASE STUDY	Batch -1 (Micro) MI 1.2: Lab diag of bacterial infection, staining tech Gram staining	Batch -1 (Pharma) PH 3.3 Perform critical evaluation of the drug promotional literature (DOAP)	PA 32.4 Diabetes mellitus PH 1.36 Pharmacotherapy of Diabetic ketoacidosis (SCD 17)	Batch -1 (Patho) PA 30.1 carcinoma cervix SGD	
	CM Batch 2:describe the concept of essential Medicine	Batch 2 – (Patho) PA 30.1 carcinoma cervix revision SGD	Batch 2 – (Micro) MI 1.2: Lab diag of bacterial infection, staining tech Gram staining	(SGD 17)	Batch 2 – (Pharma) PH 3.3 Perform critical evaluation of the drug promotional literature (DOAP)	

Time	20.12.2021	21.12.2021	22.12.2021	23.12.2021	24.12.2021	25.12.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	Clinics Lecture SURGERY SU19.1 Describe the etiology and classification of cleft lip and palate	Clinics Lecture SURGERY SU20.1 Describe the etiopathogenesis of oral cancer with symptoms and signs of oropharyngeal cancer	Internal asse	essment	, 	

9 AM- 10 AM 10-11	Clinics Lecture SURGERY SU19.2 Describe the principles of reconstruction of cleft lip and palate Clinical Posting	Clinics Lecture SURGERY SU20.2 Enumerate the appropriate investigations and discuss the Principles of treatment Clinical Posting
10-11 Am	Chinical I Osung	Chinical I Ostilig
11-12 noon	Clinics Lecture OBGY OG10.1 Define, classify and describe the aetiology, pathogenesis, clinical features, ultrasonography, differential diagnosis and management of antepartum haemorrhage in pregnancy (placenta previa)	Clinics Lecture OBGY OG10.1 Define, classify and describe the aetiology, pathogenesis, clinical features, ultrasonography, differential diagnosis and management of antepartum haemorrhage in pregnancy (Abruptio placentae)
12 PM- 1 PM	Clinics Lecture OBGY OG11.1 Describe the etiopathology, clinical features; diagnosis and investigations, complications, principles of management of multiple pregnancies	Clinics Lecture OBGY OG11.1 Describe the etiopathology, clinical features; diagnosis and investigations, complications, principles of management of multiple pregnancies
2PM – 4PM	Batch -1 (Micro) MI 1.2: Lab diag of bacterial infection, staining tech	Batch 1 – (Patho) PA 30.1 carcinoma cervix revision

Gram staining revision	
Detek 2 (Detke) DA	Detal 2 (Missee)
Batch 2 – (Patho) PA	Batch -2 (Micro)
30.1 carcinoma cervix revision	MI 1.2: Lab diag of bacterial infection,
	staining tech
	Gram staining
	revision

Time	27.12.2021	28.12.2021	29.12.2021	30.12.2021	31.12.2021	1.1.20222
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM						
2 11/2						
9 AM- 12 PM			T , 1	Assessment		

12 PM-	
1 PM	
2014	
2PM – 4PM	

DEAN



EMPLOYEES' STATE INSURANCE CORPORATION ESIC-PGIMSR & MEDICAL COLLEGE

ESIC Hospital & ODC (EZ) Diamond Harbour Road, P.O. Joka, Kolkata - 700104 <u>Tel No: (033) 24381382, Tel/Fax No: (033) 24381176</u> <u>E-mail: deanpgi-joka.wb@esic.nic.in</u>

Date: 14.01.2021

Clinical Posting Roster for Phase 2 IMG

Date	01.04.2021-	17.05.2021-	12.07.2021-	23.08.2021-	25.10.2021-	06.12.2021-
BATCH	16.05.2021	11.07.2021	22.08.2021	24.10.2021	05.12.2021	31.01.2022
		(IA 2 WEEKS)		(IA 2 WEEKS)		(IA 2 WEEKS)
A	MEDICINE	SURGERY	G & O	COM. MED.	ENT	OPTHALMOLOGY
~	(01.04.21-02.05.21)	(17.05.21-13.06.21)	(12.07.21-08.08.21)	(23.08.21-19.09.21)	(25.10.21-	(06.12.21-
	(01.04.21 02.05.21)	(17.05.21 15.00.21)	(12.07.21 00.00.21)	(23.00.21 13.03.21)	21.11.21)	16.01.22)
	RESP. MED.	ORTHOPAEDICS	PAEDIATRICS	SKIN	RADIOLOGY	PSYCHIATRY
	(03.05.21-16.05.21)	(14.06.21-11.07.21)	(09.08.21-22.08.21)	(20.09.21-24.10.21)	(22.11.21-	(17.01.22-
					05.12.21)	31.01.22)
В	OPTHALMOLOGY	MEDICINE (17.05.21-	SURGERY	G & O	COM. MED.	ENT
	(01.04.21-02.05.21)	13.06.21)	(12.07.21-08.08.21)	(23.08.21-19.09.21)	(25.10.21-	(06.12.21-
					21.11.21)	16.01.22)
	PSYCHIATRY	RESP. MED.	ORTHOPAEDICS	PAEDIATRICS	SKIN	RADIOLOGY
	(03.05.21-16.05.21)	(14.06.21-11.07.21)	(09.08.21-22.08.21)	(20.09.21-24.10.21)	(22.11.21-	(17.01.22-
					05.12.21)	31.01.22)
С	ENT	OPTHALMOLOGY	MEDICINE	SURGERY	G & O	COM. MED.
	(01.04.21-02.05.21)	(17.05.21-13.06.21)	(12.07.21-08.08.21)	(23.08.21-19.09.21)	(25.10.21-	(06.12.21-
					21.11.21)	16.01.22)
	RADIOLOGY	Psychiatry	RESP. MED.	ORTHOPAEDICS	PAEDIATRICS	SKIN
	(03.05.21-16.05.21)	(14.06.21-11.07.21)	(09.08.21-22.08.21)	(20.09.21-24.10.21)	(22.11.21-	(17.01.22-
					05.12.21)	31.01.22)
D	COM. MED.	ENT	OPTHALMOLOGY	MEDICINE	SURGERY	G & O
	(01.04.21-02.05.21)	(17.05.21-13.06.21)	(12.07.21-08.08.21)	(23.08.21-19.09.21)	(25.10.21-	(06.12.21-
					21.11.21)	16.01.22)
	SKIN	RADIOLOGY	PSYCHIATRY	RESP. MED.	ORTHOPAEDICS	PAEDIATRICS
	(03.05.21-16.05.21)	(14.06.21-11.07.21)	(09.08.21-22.08.21)	(20.09.21-24.10.21)	(22.11.21-	(17.01.22-
					05.12.21)	31.01.22)
E	G & O	COM. MED.	ENT	OPTHALMOLOGY	MEDICINE	SURGERY
	(01.04.21-02.05.21)	(17.05.21-13.06.21)	(12.07.21-08.08.21)	(23.08.21-19.09.21)	(25.10.21-	(06.12.21-
					21.11.21)	16.01.22)
	PAEDIATRICS	SKIN	RADIOLOGY	PSYCHIATRY	RESP. MED.	ORTHOPAEDICS
	(03.05.21-16.05.21)	(14.06.21-11.07.21)	(09.08.21-22.08.21)	(20.09.21-24.10.21)	(22.11.21-	(17.01.22-
					05.12.21)	31.01.22)
F	SURGERY	G & O	COM. MED.	ENT	OPTHALMOLOGY	MEDICINE
	(01.04.21-02.05.21)	(17.05.21-13.06.21)	(12.07.21-08.08.21)	(23.08.21-19.09.21)	(25.10.21-	(06.12.21-
					21.11.21)	16.01.22)
	ORTHOPAEDICS	PAEDIATRICS	SKIN	RADIOLOGY	PSYCHIATRY	RESP. MED.
		(14.06.21-11.07.21)	(09.08.21-22.08.21)	(20.09.21-24.10.21)	(22.11.21	(17.01.22-
	(03.05.21-16.05.21)	(14.00.21-11.07.21)	(09.08.21-22.08.21)	(20.09.21-24.10.21)	(22.11.21- 05.12.21)	(17.01.22-

- Batch A- 1-17 Batch B- 18-34
- Batch C- 35-51 Batch D- 52-68
- Batch E- 69-85 Batch F- 86- REST